Point72 entities disclose 1.4% Cidara Therapeutics (CDTX) stake in Schedule 13G/A

Rhea-AI Filing Summary

Cidara Therapeutics, Inc. received an updated ownership report from Point72 affiliates and Steven A. Cohen stating beneficial ownership of 450,000 shares of common stock as of December 31, 2025. This represents 1.4% of the outstanding shares, including 200,000 shares issuable upon exercise of call options.

The shares are held through an investment fund managed by Point72 Asset Management, L.P., with Point72 Capital Advisors, Inc. as its general partner and Mr. Cohen controlling both entities. The filers certify the securities are not held for the purpose of changing or influencing control of Cidara Therapeutics.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 3)

Cidara Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

171757206

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Point72 Asset Management, L.P.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 450,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 450,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

450,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.4 %

12

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person: Includes 200,000 Shares (as defined in Item 2(a)) issuable upon exercise of call options.

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Point72 Capital Advisors, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 450,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 450,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

450,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.4 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: Includes 200,000 Shares issuable upon exercise of call options.

SCHEDULE 13G

CUSIP No. 171757206

1

Names of Reporting Persons

Steven A. Cohen

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 450,000.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 450,000.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

450,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

1.4 %

12

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person: Includes 200,000 Shares issuable upon exercise of call options.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cidara Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 6310 Nancy Ridge Drive, Suite 101, San Diego, CA 92121
Item 2.
(a)	Name of person filing: This statement is filed by: (i) Point72 Asset Management, L.P. ("Point72 Asset Management") with respect to the shares of common stock, par value $0.0001 per share ("Shares"), of Cidara Therapeutics, Inc. held by (and issuable upon the exercise of call options held by) an investment fund it manages; (ii) Point72 Capital Advisors, Inc. ("Point72 Capital Advisors Inc.") with respect to Shares held by (and issuable upon the exercise of call options held by) an investment fund managed by Point72 Asset Management; and (iii) Steven A. Cohen ("Mr. Cohen") with respect to Shares beneficially owned by Point72 Asset Management and Point72 Capital Advisors Inc.
(b)	Address or principal business office or, if none, residence: The address of the principal business office of Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902.
(c)	Citizenship: Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Mr. Cohen is a United States citizen.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 171757206
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by Item 4(a) is set forth in Row 9 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on December 31, 2025. Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by an investment fund it manages. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors Inc. The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Securities Exchange Act of 1934, the beneficial owner of the Shares reported herein.
(b)	Percent of class: 1.4%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information required by Item 4(c)(i) is set forth in Row 5 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on December 31, 2025.
	(ii) Shared power to vote or to direct the vote: The information required by Item 4(c)(ii) is set forth in Row 6 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on December 31, 2025.
	(iii) Sole power to dispose or to direct the disposition of: The information required by Item 4(c)(iii) is set forth in Row 7 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on December 31, 2025.
	(iv) Shared power to dispose or to direct the disposition of: The information required by Item 4(c)(iv) is set forth in Row 8 of the cover page for each of the Reporting Persons and is incorporated herein by reference. Such information is as of the close of business on December 31, 2025.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. See Item 2(a).
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Point72 Asset Management, L.P.

Signature:	/s/ Jason M. Colombo
Name/Title:	Jason M. Colombo, Authorized Person
Date:	02/17/2026

Point72 Capital Advisors, Inc.

Signature:	/s/ Jason M. Colombo
Name/Title:	Jason M. Colombo, Authorized Person
Date:	02/17/2026

Steven A. Cohen

Signature:	/s/ Jason M. Colombo
Name/Title:	Jason M. Colombo, Authorized Person
Date:	02/17/2026

FAQ

What ownership stake does Point72 report in Cidara Therapeutics (CDTX)?

Point72-related entities report beneficial ownership of 450,000 Cidara Therapeutics shares, representing 1.4% of the common stock. This total includes both currently held shares and those issuable upon exercise of call options as of December 31, 2025.

Who are the reporting persons in this Cidara Therapeutics (CDTX) Schedule 13G/A?

The reporting persons are Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen. They report beneficial ownership of Cidara Therapeutics shares through an investment fund managed by Point72 Asset Management, with Mr. Cohen controlling the involved entities.

How many Cidara Therapeutics (CDTX) shares reported by Point72 are tied to options?

Out of the 450,000 beneficially owned Cidara shares, 200,000 are issuable upon exercise of call options. The remaining shares are currently held by an investment fund managed by Point72 Asset Management as of the December 31, 2025 measurement date.

Does the Point72 filing for Cidara Therapeutics (CDTX) indicate an attempt to gain control?

The filers certify that the Cidara Therapeutics securities were not acquired and are not held to change or influence control of the company. They also state the holdings are not in connection with any control-related transaction, other than limited nomination-related activities.

What voting and dispositive power does Point72 report over Cidara Therapeutics (CDTX) shares?

The reporting persons disclose shared voting and shared dispositive power over 450,000 Cidara Therapeutics shares, with no sole voting or dispositive power. These powers arise from Point72 Asset Management’s investment management agreement with the investment fund holding the securities.

Why is this Cidara Therapeutics (CDTX) filing labeled as an amendment to Schedule 13G?

The document is Amendment No. 3 to a Schedule 13G, reflecting updated ownership information as of December 31, 2025. Such amendments are filed when previously reported beneficial ownership levels change or require confirmation at a new year-end date.